Disease: Leukemogenesis ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE These results support the concept that the BCR-ABL chimeric gene plays a crucial role in leukemogenesis but suggest that factors other than the position of the breakpoint in the BCR gene determine the lineage of the target cell for malignant transformation. 3179449 1988
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 GeneticVariation disease BEFREE Recently, the absence of bcr rearrangement and expression of a distinct aberrant 190-kd abl protein (p190c-abl) has been described in Ph-positive ALL, with the suggestion that the two abl variants may be pathogenetically associated with myeloid v lymphoid leukemogenesis. 3311207 1987
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE A high frequency of aneuploidy was found in advanced leukemia indicating a primary and pivotal role for BCR/ABL in leukemogenesis. 8251894 1993
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE These results indicate that SJT of ABL and/or CD3 (MLL) genes is associated with the leukemogenesis of secondary leukemia. 9002963 1997
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE Together, these results suggest that FUS might function as a regulator of BCR/ABL leukemogenesis, promoting growth factor independence and preventing differentiation via modulation of cytokine receptor expression. 9687511 1998
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE Together, these data support the important role of a Rac-dependent pathway(s) controlling motility in BCR/ABL-mediated leukemogenesis. 9751755 1998
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 GeneticVariation disease BEFREE This cell line, MY, expressing a novel variant P180BCR/ABL protein with a deletion of the a2 exon of the ABL gene, may be useful for elucidating the pathophysiology of this fusion protein and for studying ETV6-related leukemogenesis and t(2;3), as well as the molecular mechanisms of the complex translocations. 9790503 1998
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE Expression of normal ABL and BCR and of reciprocal fusion genes BCR-ABL and ABL-BCR was examined in a panel of 53 BCR-ABL-positive cell lines by RT-PCR to determine the influence of the various transcripts on leukemogenesis. 10576511 1999
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 AlteredExpression disease BEFREE Together, these data support the importance of anti-apoptotic pathways for BCR/ABL-dependent leukemogenesis and suggest that Bcl-2 expression promotes secondary changes leading to a more aggressive tumor phenotype.(Blood.2000;96:3915-3921) 11090078 2000
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE This article summarizes recent progress in modeling human Philadelphia-positive leukemia in mice with the retroviral bone marrow transduction/transplantation system and emphasizes the advantages and limitations of this approach with examples from the BCR-ABL leukemogenesis literature. 11358380 2001
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE The BCR-ABL fusion gene is important for the leukemogenesis of chronic myeloid leukemia (CML). 11378554 2001
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 GeneticVariation disease BEFREE The absence of differences between the patients with and without 3' BCR deletion supports the hypothesis that the hybrid gene ABL-BCR does not have an important role in leukemogenesis in CML cases. 11672777 2001
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE Examination of the signaling pathways differentially regulated by the Bcr-Abl proteins will help us gain better insight into Bcr-Abl mediated leukemogenesis. 12191565 2002
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE Thus, La-dependent activation of mdm2 translation might represent an important molecular mechanism involved in BCR/ABL leukemogenesis. 12620409 2003
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE This may be due to a deletion of the ABL exon 2 sequences, which are an essential part of the ABL SH3 domain inducing STAT5 expression, which is indeed crucial for the BCR/ABL leukemogenesis; because of its role in anti-apoptotic activity and cell cycle progress. 12688363 2003
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE To obtain comprehensive information about the genes involved in BCR/ABL-dependent leukemogenesis, samples from 15 chronic myelogenous leukemia (CML) patients and seven normal donors were analysed using a cDNA microarray assay. 12813469 2003
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE Previous studies suggested that the SH2-containing inositol-5-phosphatase (SHIP) may play a tumor suppressor-like function in BCR-ABL-mediated leukemogenesis. 12829595 2003
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE By stable and conditional expression of ICSBP in wild-type and BCR/ABL-transformed 32D cells (32D/wt and 32D/BA), we found that ICSBP inhibited BCR/ABL-mediated leukemogenesis in vivo. 14656881 2004
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE The established cell lines may prove useful in further modeling and dissection of BCR/ABL-induced leukemogenesis. 14712293 2004
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE This is the first report of an ALL case with ABL amplification, and the authors speculate that both ABL proto-oncogene amplification and the p16(INK4a) tumor suppressor gene deletion have been implicated in leukemogenesis in the present case, although whether the ABL amplification truly contributes to the leukemogenesis or merely an epiphenomenon representing underlying genomic instability remains to be determined. 15282669 2004
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE Of these, activation of phosphoinositide 3-kinase (PI3K) has emerged as one of the essential signaling mechanisms in ABL leukemogenesis. 15781610 2005
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE Originally identified in chronic myelogenous leukemia cells as a highly phosphorylated substrate for the chimeric p210(bcr-abl) protein, DOK1 was suspected to play a role in leukemogenesis. 16823827 2006
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. 17925491 2008
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE Apart from providing important pathogenetic insights into BCR/ABL1-mediated leukemogenesis, the present study also provides a number of pathways/individual genes that may provide attractive targets for future development of targeted therapies. 18181176 2008
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.100 Biomarker disease BEFREE Here we examined the effect of Ras inhibition by a dominant negative mutant of Ras, N17 H-Ras, in adult hematopoiesis and in BCR/ABL leukemogenesis using the mouse bone marrow transduction and transplantation approach. 18577264 2008